The radiolabeled serotonin transporter (SERT) ligand [ 11 C](+)-McN5652 has recently been used in clinical positron emission tomography (PET) studies for SERT imaging. However, this radioligand offers disadvantages in routine clinical settings because of its short radioisotope half-life (eg PET facilities within hospitals without a cyclotron need to acquire such radioligands from distant cyclotron units for clinical use).
INTRODUCTION
Although there is a vast body of evidence that the serotonin transporter (SERT) in the brain is involved in various psychiatric disorders such as depression, anxiety, suicidality, obsessive compulsive disorder, schizophrenia, and others (Heinz et al, 1998; Menza et al, 1999; Bondy et al, 2000; Dahlström et al, 2000; Laruelle et al, 2000; Saxena et al, 2002; Tsai et al, 2002) , its specific role in different emotional, motivational, and cognitive dysfunctions remains to be elucidated. Owing to the emerging socioeconomic impact of these neuropsychiatric disorders, there is a growing need in developing neuroimaging techniques to evaluate the availability and function of the SERT in the living human brain. Positron emission tomography (PET) as well as single-photon emission tomography (SPECT) enables to visualize the SERT in vivo (Hesse et al, 2003) , whereby PET offers the advantages of higher spatial resolution and the possibility for absolute quantification compared with SPECT.
Although many drugs showing a high in vitro binding to the SERT have been used as templates for the development of radioligands for PET, most of them have been found to be unsuitable because of their insufficient selectivity .
In 1992, [
11 C]McN5652 was introduced as a new radioligand for SERT imaging with PET (Suehiro et al, 1992) . It has been used for quantification of the SERT in the normal human brain Buck et al, 2000; Parsey et al, 2000; Ikoma et al, 2002) and in patients intoxicated with MDMA (McCann et al, 1998; Ricaurte et al, 2000) , with social phobia (Kent et al, 2002) , major depression , and bipolar disorder . However, its rather high nonspecific binding in the brain and its slow release from the specific binding sites Buck et al, 2000) promoted the search for alternatives, as is also indicated by some SPECT studies with [ 123 I]-b-CIT which provided opposite results in similar patient populations (ie depression; Malison et al, 1998) . On the other hand, SERT data obtained by [ 11 C]McN5652/PET (Yamamoto et al, 2002) and [ 123 I]-b-CIT/SPECT (Hesse et al, 2003) have been very consistent. Thus, there is a necessity to create and make use of sufficient reliable SERT radiopharmaceuticals which should be designed to prevent confounding findings. The 11 C-labeled radioligands N,N-dimethyl-2-(2-amino-4-methoxyphenylthio)benzylamine (DAPP) and N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine (DASB) have also been introduced for SERT imaging in humans, and it has been shown that [ Alternatively, various attempts have been made to synthesize an SERT radioligand labeled with the longerlived isotope 18 F. Karramkam et al (2002) synthesized an 18 F-labeled derivative of 6-nitroquipazine as a radioligand for the in vivo SERT imaging, but concluded that the compound does not have the expected potential for PET imaging. In a preliminary communication, Huang et al (2002) (Zessin et al, 2001) . The replacement of hydrogen by fluorine at the S-methyl group of McN5652 reduced the affinity to the 5-HT transporter only slightly and studies with [
18 F](+)-FMe-McN5652 in rats and pigs revealed that this radiotracer might be suitable for in vivo imaging of the SERT in humans Marjamäki et al, 2003) . Ex vivo autoradiographic studies in rats showed marked accumulation in brain regions with a known high density of the 5-HT transporter such as raphe nuclei, substantia nigra, thalamus, and amygdala. A maximum activity concentration ratio of 9 between brain regions with specific binding (raphe nuclei) and without specific binding (cerebellum) was reached within 3.5 h after tracer administration (Marjamäki et al, 2003) . First PET studies in pigs revealed that the highest accumulation of [ 18 F](+)-FMeMcN5652 was found in the ventral midbrain, thalamus, olfactory lobe, and pons . A strong inhibition of the specific binding was observed after pretreatment with the selective 5-HT uptake inhibitor citalopram.
The present study was performed to investigate the in vivo kinetics of [ (Zessin et al, 1999 (Zessin et al, , 2001 . Briefly, the thioester precursors were prepared from enantiomerically pure (+)-McN5652 or (À)-McN5652 by Sdemethylation with sodium amide, followed by conversion of the thiols with acetyl chloride.
METHODS

Synthesis of Radiotracers
The hydrolized thioester precursor and [ (Ziegler, 1991) . The Becke-Perdew (BP86) functional with Becke's gradient correction for the local expression of the exchange energy (Becke, 1988 ) and Perdew's gradient correction for the local expression of the correlation energy (Perdew, 1986) was used. The numerical polarization basis set DN* leading to pBP/DN* model was chosen. The starting conformations of ligands were obtained by force-field calculations using the MMFF94 force field (Halgren, 1996) . Charge distribution calculations were performed based on fitting of the electrostatic potential leading to electrostatic charges (Breneman and Wiberg, 1990) .
The detailed synthesis of [ 18 F](+)-FMe-McN5652 was described recently (Zessin et al, 2001) . Briefly, demethylated (+)-McN5652 (prepared from the corresponding thioester precursor) was reacted with [
18 F]bromofluoromethane 
Animals and Drugs
All procedures involving animals were carried out according to the 'Principles of laboratory animal care ' (NIH publication No. 86-23, revised 1985) , and following the German Law on the Protection of Animals. Female pigs (Deutsches Landschwein/Deutsches Edelschwein Â Pietrain, 13-17 kg) were used. They were deprived of food, but not of water, for 24 h prior to delivery to the laboratory. 
Positron Emission Tomography
In all, 28 6-week-old farm-bred female pigs were studied with PET under general anesthesia (0.5% isoflurane in a gas mixture of 70% nitrous oxide and 30% oxygen, via endotracheal tube using a volume-controlled ventilator). Pancuronium was infused at a rate of 0.3 mg kg À1 h
À1
. Blood gases, end-tidal CO 2 , and body temperature were continuously monitored. The radiotracer was infused as a smooth bolus into the left jugular vein over 2 min. v.) . PET imaging (35 dynamic time frames of length between 0.5 and 10 min, total scan duration: 120 min) was performed with an ECAT EXACT HR+ (CTI/Siemens) scanner, at a spatial resolution (transaxial) of 4-5 mm (Brix et al, 1997) . Reconstruction of both PET scans was performed using filtered back projection with a Hanning filter (cutoff frequency of 0.5). For attenuation and scatter correction, a transmission scan using three rotating 68 Ge rod sources was performed prior to the emission scan. Radioactivity data of selected volumes of interest (VOI) were obtained using a standardized procedure, which was recently described in detail . Briefly, irregular VOIs defined on MR images were aligned to the added PET radioactivity images interactively using an 'in-house' data analysis tool.
During the PET scans, 31-47 discrete arterial blood samples (about 0.2 ml each) were obtained at defined time points starting with the onset of radiotracer infusion, and in intervals between 15 s and 30 min. The samples were immediately stored on ice and centrifuged at 3000g for plasma sampling and counting in a g-counter that was crosscalibrated to the PET camera. The calibration factor was used to calculate absolute values of radioactivity from the counts per minute (cpm) values obtained from the counter. Between six and 11 additional blood samples were obtained for HPLC analysis of plasma metabolites. After centrifugation, 0.5 ml plasma was obtained and precipitated with ethanol (plasma : EtOH ¼ 1 :
). Metabolite analysis was carried out by gradient HPLC in the following configuration: Hewlett-Packard 1100 quaternary gradient pump, autosampler (900 ml sample loop; injection volume 500-900 ml), UV detector (l ¼ 254 nm), all parts of the Hewlett-Packard 1100 system, and a flow scintillation analyzer (150 TR, Canberra Packard) with a PET flow cell (100 ml volume; energy window: 80-1750 keV). The analytes were separated on Merck RP-18e column (Purospher, 125 Â 3 mm, 5 mm) at a temperature of 281C. A binary gradient was chosen at a flow rate of 0.75 ml min À1 (0-1 min 23% B, 5-11 min 70% B; total method time: 11 min). Mobile phase A consisted of 0.1 M ammonium formate, pH 7.0. Mobile phase B was MeCN. The metabolite data were fitted to an empiric function, the parameters of which were then used for the correction of the plasma input function.
Data Analysis and Model Description
The general model for the description of the binding of PET ligands in vivo to drug-binding sites was introduced by Mintun et al (1984) . For the analysis of [
11 C](+)-McN5652 binding to the SERT, only the simplified structures of the one-and two-tissue compartment models (Koeppe et al, 1991; Buck et al, 2000) were used to describe the binding of the radioligand in the pig brain ( Figure 1 ). In these two compartmental models, the total radiotracer accumulation in the brain regions, M(t), can be described by
where M t (t) is the total amount of radiotracer in the brain tissue (one-tissue compartment model, Equation (1)). M f (t) represents the free and nonspecifically bound radiotracer in the brain tissue and M b (t) the regional content of the radiotracer specifically bound to the SERT (two-tissue compartment model, Equation (2)).
Following the common notation of Koeppe et al (1991) , the ordinary differential equations that describe the time courses of radioactivity contents in these models are one-tissue compartment model:
two-tissue compartment model: Figure 1 One-(a) and two-tissue compartment models (b) for radiotracer distribution in the porcine brain. C a , arterial plasma concentration of the radiotracer; M t , total radiotracer amount in brain tissue; M f , free and nonspecifically bound amount of the radiotracer; M b , radiotracer amount specifically bound to the SERT.
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is the unidirectional clearance of the ligand from plasma to tissue. C a (t) is the concentration of parent radioligand in arterial plasma as a function of time t. The rate constants k 2 0 , k 2 00 , k 3 0 , and k 4 are given in min À1 . The rate constants were estimated by weighted nonlinear least-squares fits to the decay-corrected tissue time-activity curves using the simplex method (Nelder and Mead, 1965) .
Distribution volumes (DV) were calculated to provide parameter estimates related to binding of the radiotracer to the serotonin transporter. In PET, the total DV is the partition ratio between the total concentration of ligand in the tissue and that in plasma which would be attained in a steady-state equilibrium between the two (Cunningham and Lammertsma, 1995) . DV is given in (ml plasma) (ml tissue)
À1
. With the one-tissue compartment model, the total distribution volume DV 00 is equal to K 1 /k 2 00 . From the region-to-occipital cortex ratio of DV 00 , the transporter occupancy (in %) was defined as the per cent reduction of the ratio after administration of citalopram, when compared with the ratio at baseline (Farde et al, 1997; Kent et al, 2002) . With the two-tissue compartment model, the total distribution volume DV t is equal to K 1 /k 2 0 (1+k 3 0 /k 4 ) (Koeppe et al, 1991) .
Furthermore, two parameters more directly related to the ratio B max 0 /K D were calculated for the two-tissue compartment model:
0 is the concentration of maximum available receptor sites in competition with endogenous and infused cold ligand. K D is the aqueous equilibrium ligand-dissociation constant. BP ¼ B max 0 /K D is the binding potential and is unitless (Mintun et al, 1984) . f 1 is the free fraction of the radiotracer in plasma (unitless). f 2 is the free fraction of the radiotracer in tissue and is unitless.
These outcome measures have been given different names in the PET literature. Laruelle et al (1994) referred to f 2 BP as V 3 00 and to
is also equal to the distribution volume of the specific binding compartment relative to the plasma input, as used by Buck et al (2000) in their assessment of methods.
For the estimation of the parameters of the two-tissue compartment model, different parameter constraints were used. These constraints were:
1. the blood volume V 0 fixed at 0.05 (Lin et al, 1999) ; 2. the ratio K 1 /k 2 0 fixed; 3. the ratio K 1 /k 2 0 fixed and a fixed blood volume V 0 .
For coupling of K 1 and k 2 0 , the mean values of the regional parameters were used, as estimated after complete blockade of the specific binding to the SERT by pretreatment with citalopram. Goodness of fit of the different models was assessed using the F-test and the Akaike information criterion (AIC) (Akaike, 1974; Hawkins et al, 1986) . A significant improvement of the fit using model B instead of model A is indicated by F-values of 44.15 (Po0.05) or AIC (model B)oAIC (model A).
The data are mean values 7 standard deviation (SD). The coefficient of variation (COV) was calculated by mean/ SD Â 100. The t-test was used to evaluate significant differences. Figure 3a , and compared with the corresponding input functions of the 11 C-labeled derivative (Figure 3b ). There are no significant differences between both radiotracers. To test this assumption, the area under the curve and the peak radioactivity levels of both input functions were compared using the t-test. Preinjection of citalopram resulted in an increase of both tracer input functions throughout the whole study. However, the estimated rate constant for blood-brain transfer (K 1 ) remained unchanged (98% of In vivo measurement of the serotonin transporter P Brust et al control). The fitted blood volume decreased by about 17% (pp0.10).
RESULTS
Coronal
In separate plasma samples, the metabolism of both radiotracers was investigated by HPLC. Figure 4 shows the relative amounts of the parent compounds in the samples in dependency on the time of injection. The overlapping of the two functions indicates that the rate of peripheral metabolism of both radiotracers is nearly identical. As can be seen from chromatograms obtained 12 min after radiotracer injection (Figure 5 ), even the metabolite profiles measured on the HPLC system are similar. Occasionally, small negligible amounts of a lipophilic metabolite were detectable for both radioligands although the relative amounts were higher for [ (o1% at 20 min, 2-3% at 120 min). The peripheral radiotracer metabolism was unchanged after preinjection of citalopram or maprotiline (data not shown).
Various compartmental models were used for quantification of the brain uptake of Figure 6 . The solid lines in this figure represent the model fits using an unconstrained two-tissue compartment model. Table 1 shows the calculated rate constants according to this model. The 18 F-labeled derivative has an about 30% higher influx rate constant, K 1 , with a 50% lower COV than the . If constrained models were used, the regionto-occipital cortex ratios increased by more than a factor of 10. However, this was accompanied by a considerable increase (about a factor of 2-3) of the COVs (data not shown).
The binding parameter f 1 BP (obtained from the unconstrained fit) was found to be the one that correlates best with the SERT density, as determined by in vitro autoradiography with [ 3 H]citalopram on the porcine brain (Cumming et al, 2001; Kretzschmar et al, 2003) . This highly significant correlation is shown in Figure 7 for both radiotracers.
DISCUSSION
The results of PET studies performed in piglets indicate that In vivo measurement of the serotonin transporter P Brust et al ligands specific for different types of receptors and transporters have been developed to measure abnormalities in the binding potentials of distinct receptors in neuropsychiatric disorders. However, much remains unclear about the function and disturbed function of each transmitter system, or of the complex transmitter network itself. The serotonin transporter is one of the sites of major interest in brain neurochemical research, because modern psychopharmaceuticals, that is the selective serotonin reuptake inhibitors (SSRI), act effectively on these structures in depression, anxiety, social phobia, obsessive-compulsive disorder, and post-traumatic stress ( Ables and Baughman, 2003) . Owing to the socioeconomic burden of neuropsychiatric diseases (Lopez and Murray, 1998) , there is an increasing demand not only for a reliable research, but also for a diagnostic tool to image the pathophysiology of these disorders in vivo. Recently, we have described the synthesis of [ 18 F](+)-FMe-McN5652 as a potential PET radioligand for the serotonin transporter (Zessin et al, 2001 ). Compared to [
, it has a lower affinity of K i ¼ 2.3 nM, which in turn leads to a faster equilibration in PET studies. As pointed out by Halldin et al (2002) , the applicability of many previously introduced PET radioligands for the serotonin transporter suffered from too small K i values, and a tracer with a K i of 1.96 nM was proposed as well suited for in vivo quantification. The increased counting statistics at later times of the PET scan favors further the . The maximum target-nontarget ratio in vitro was 21 in rats and 15 in pigs . Ex vivo autoradiography in rats revealed a ratio of 9 in the raphe nuclei (Marjamäki et al, 2003) . PET studies performed in pigs revealed a midbrainoccipital cortex ratio of about 2 for both radioligands [ . However, such target-to-nontarget uptake ratios are not a precise measure for the SERT density, because neither a full kinetic equilibrium nor a 'pseudoequilibrium' has been reached during these studies.
The present study demonstrates that citalopram is able to block most of the sites (97%) available for binding of [
Citalopram is a very selective SERT inhibitor with no effects on dopaminergic or noradrenergic uptake systems (Christensen et al, 1977; Hyttel, 1977) . A usual problem with giving massive doses of i.v. SERT inhibitors (in our case: 5 mg kg À1 ) is that one cannot be certain that regional cerebral blood flow was not affected. Clomipramine (0.15 mg kg
À1
) administered into humans caused a selective decrease of CBF in the dorsomedial nucleus of the thalamus (Smith and Geday, 2001 ). Citalopram, given to patients with social phobia, also elicited a blood flow decrease in selected brain regions (Furmark et al, 2002) . In rats, citalopram (10 mg kg À1 ) reduced the CBF in nine of 27 brain areas analyzed. In vivo measurement of the serotonin transporter P Brust et al Concomitantly, the glucose utilization was decreased, and it was suggested that the blood flow reduction may be entirely explained by the secondary effects of depressed metabolic demand induced by citalopram (McBean et al, 1999) . In our study, only small blood flow changes are expected. The cerebral blood volume estimated using compartmental modeling was only slightly decreased and the flowdependent blood-brain transfer (K 1 ) was unchanged. Therefore, the decreased radiotracer accumulation observed after preinjection of citalopram (Figure 2b) (Coenen et al, 1986; Petric et al, 1999) . The radiotracer was prepared in a mixture of ethanol and 0.11 M sodium bicarbonate solution (1 : 1 v v À1 ). This solvent mixture has been proven to provide stability for a period of at least 120 min (Zessin et al, 2001) . It has a purity of 495%. The remaining o5% included only polar products. A further 1 : 1 dilution with saline immediately prior to injection did not cause a measurable degradation of the radiotracer. Lipophilic radiolabeled metabolites were only detectable at later scan times, and included less than 5% of the total radiotracer amount.
After injection, a nearly identical metabolic pattern was observed for the The rate of radiotracer metabolism in the piglet is comparable to that in humans. Szabo et al (1999) have found 14 7 6% of the unmetabolized [
11 C](+)-McN5652 in human plasma at 60 min p.i. In our study, we have determined an identical value (14.1 7 5.8%) at this time. For the 18 F-labeled derivative, a slightly higher value was found (16.1 7 3.3%).
Based on the metabolite-corrected arterial plasma input functions, we have calculated parameters related to the blood-brain transfer of the radioligands, and those related to the binding to the SERT. K 1 , which describes the tracer uptake across the blood-brain barrier, is about 20-30% higher for [ 0 is about 80-100% higher for the 18 F-labeled tracer, indicating a faster kinetics of this compound as has been mentioned recently . The exchange of the methylthio group by the fluoromethylthio moiety leads to changes in the charge density. The hydrogenfluorine exchange results in a shift of the negative charge center from sulfur to the fluorine atom. Furthermore, the calculated dipole moment increased from Parsey et al, 2000) , and others the two-tissue compartment model (Buck et al, 2000) or a graphical method with a reference tissue input function (Buck et al, 2000; Ikoma et al, 2002) . The various parameter estimates obtained from these models contain a similar amount of information on serotonin transporters. However, none of them reflects the SERT density in a fully quantitative manner (Buck et al, 2000) . The parameter that is expected to come closest to the binding potential BP (Mintun et al, 1984) is the k 3 0 /k 4 ratio ( ¼ f 2 BP). However, the direct estimation of k 3 0 and k 4 is very sensitive to noise, which associates high errors with them (Cunningham and Lammertsma, 1995) . Also, in our study with [ , it was only a factor of 2.6. The difference between both tracers is even larger if DV t is compared. In a previous study, we have estimated the specific binding from the difference in tracer uptake at later scan times between a region and the occipital cortex, assuming negligible specific binding in the latter. The data indicated a higher specific binding for [ McN5652 . However, the estimation was biased because no pseudoequilibrium was reached for either of the tracers. The estimation of f 2 BP or of DV t after bolus injection is independent of an equilibrium state, and therefore a better estimate of the specific binding. The discrepancy between both studies may have been caused by the faster kinetics of (Houle et al, 2000) , calculated with the ratio method, was observed in the hypothalamus . The estimated value (2.5) is similar to f 2 BP (R v ¼ 2.42) obtained in the human thalamus using 
